Optimal dosing and duration of linezolid in multidrug-resistant tuberculosis: methodological and clinical appraisal

Affiliations

Comment

Weiliang Cao. Eur Respir J. 2026.

. 2026 Jan 22;67(1):2501804.

doi: 10.1183/13993003.01804-2025. Print 2026 Jan.

¹ Department of Clinical Laboratory, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China 790561571@qq.com.

No abstract available

Conflict of interest statement

Conflict of interest: W. Cao has no potential conflicts of interest to disclose.

Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysis.
Kwak N, Kim JY, Han A, Berry C, Beumont M, Tweed C, Crook A, Dheda K, Fabiane S, Fadeyi MO, Foraida S, Gils T, Hoang TTT, Jham MA, Murphy RA, Nguyen BH, Nguyen TMP, Nyang'wa BT, Oelofse S, Hahn S, Yim JJ. Kwak N, et al. Eur Respir J. 2025 Aug 22;66(2):2500315. doi: 10.1183/13993003.00315-2025. Print 2025 Aug. Eur Respir J. 2025. PMID: 40675768 Free PMC article.